Metis Global Partners LLC Acquires 280 Shares of Solventum Co. (NYSE:SOLV)

Metis Global Partners LLC lifted its holdings in Solventum Co. (NYSE:SOLV) by 6.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,728 shares of the company’s stock after purchasing an additional 280 shares during the quarter. Metis Global Partners LLC’s holdings in Solventum were worth $312,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in SOLV. Hotchkis & Wiley Capital Management LLC acquired a new position in Solventum during the third quarter worth $125,488,000. Trian Fund Management L.P. increased its holdings in Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after buying an additional 1,765,676 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Solventum during the third quarter worth $50,948,000. Nordea Investment Management AB increased its holdings in Solventum by 189.5% during the fourth quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock worth $43,902,000 after buying an additional 431,986 shares during the last quarter. Finally, General American Investors Co. Inc. acquired a new position in Solventum during the third quarter worth $14,456,000.

Solventum Stock Down 2.8 %

SOLV stock opened at $75.69 on Friday. The firm has a 50-day moving average price of $73.42 and a 200-day moving average price of $70.42. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The stock has a market capitalization of $13.08 billion and a P/E ratio of 27.52.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Wells Fargo & Company upped their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Piper Sandler upped their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Bank of America upped their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Mizuho upped their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday. Finally, The Goldman Sachs Group upped their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.